Advances in Predictions of Oral Bioavailability of Candidate Drugs in Man with New Machine Learning Methodology.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
28 Apr 2021
Historique:
received: 22 03 2021
revised: 20 04 2021
accepted: 22 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 25 5 2021
Statut: epublish

Résumé

Oral bioavailability (F) is an essential determinant for the systemic exposure and dosing regimens of drug candidates. F is determined by numerous processes, and computational predictions of human estimates have so far shown limited results. We describe a new methodology where F in humans is predicted directly from chemical structure using an integrated strategy combining 9 machine learning models, 3 sets of structural alerts, and 2 physiologically-based pharmacokinetic models. We evaluate the model on a benchmark dataset consisting of 184 compounds, obtaining a predictive accuracy (

Identifiants

pubmed: 33925103
pii: molecules26092572
doi: 10.3390/molecules26092572
pmc: PMC8124353
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Drug Metab Dispos. 2011 Feb;39(2):265-74
pubmed: 21051535
Drug Metab Dispos. 2011 Sep;39(9):1633-42
pubmed: 21632965
Cancer Res. 1998 Aug 1;58(15):3248-53
pubmed: 9699650
Xenobiotica. 2008 Oct;38(10):1313-29
pubmed: 18853387
BMC Bioinformatics. 2007 Feb 22;8:59
pubmed: 17316423
J Med Chem. 2005 Jan 27;48(2):604-13
pubmed: 15658873
J Pharm Sci. 2010 Jul;99(7):3246-65
pubmed: 20166204
J Chem Inf Model. 2014 Nov 24;54(11):3211-7
pubmed: 25318024
BMC Bioinformatics. 2009 Dec 03;10:397
pubmed: 19958528
Int J Clin Pharmacol Ther Toxicol. 1989 Apr;27(4):179-211
pubmed: 2654032
J Chem Inf Comput Sci. 2003 May-Jun;43(3):721-34
pubmed: 12767130
Eur J Pharm Sci. 2014 Jun 16;57:280-91
pubmed: 23988844
J Med Chem. 2006 Nov 16;49(23):6660-71
pubmed: 17154497
Xenobiotica. 2017 Sep;47(9):741-751
pubmed: 27560606
J Pharm Sci. 2011 Oct;100(10):4127-57
pubmed: 21541937
Xenobiotica. 2010 Sep;40(9):637-49
pubmed: 20624033

Auteurs

Urban Fagerholm (U)

Prosilico AB, Lännavägen 7, SE-141 45 Huddinge, Sweden.

Sven Hellberg (S)

Prosilico AB, Lännavägen 7, SE-141 45 Huddinge, Sweden.

Ola Spjuth (O)

Prosilico AB, Lännavägen 7, SE-141 45 Huddinge, Sweden.
Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, Box 591, SE-751 24 Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH